Skip to content

Tirzepatide

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

SStrongWell-StudiedEspañolFrançais
Last updated 59 citations
TL;DR

Tirzepatide is a medicine that acts on two gut hormones (GIP and GLP-1) to reduce hunger and control blood sugar. It's FDA-approved for type 2 diabetes (Mounjaro) and weight loss (Zepbound), and it produced the biggest weight loss of any approved drug — around 20% or more in trials. Studies also found it helped with sleep apnea and fatty liver.

What is Tirzepatide?

Tirzepatide is the first dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It has produced the largest weight loss of any approved medication: in SURMOUNT-1, mean reduction at 72 weeks was 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg against 3.1% on placebo, on the trial's primary treatment-regimen estimand.

What Tirzepatide Is Investigated For

Tirzepatide produces the largest weight loss of any FDA-approved medication — the SURMOUNT-1 trial showed 20.9% weight loss at 72 weeks, and the head-to-head SURMOUNT-5 trial confirmed superiority over semaglutide (20.2% vs 13.7%). Its dual GIP/GLP-1 mechanism also delivers superior glycemic control in type 2 diabetes, with HbA1c reductions of 2.01, 2.24 and 2.30 percentage points at 5, 10 and 15 mg versus 1.86 for semaglutide 1 mg in the head-to-head SURPASS-2 trial. Cardiovascular outcomes evidence has matured substantially in 2026: the SURPASS-CVOT trial (n=13,165, median 4 years) established tirzepatide non-inferior to dulaglutide for the primary composite CV outcome (NEJM 2025, PMID 41406444; HR 0.92, 95.3% CI 0.83–1.01), which in August 2026 added a major-cardiovascular-event risk-reduction indication to the Mounjaro label, with a JAMA Cardiology post hoc analysis (PMID 41903177) characterizing the cardiorenal outcome profile and a pre-specified kidney analysis (PMID 42114520) showing a 23% reduction in major kidney events vs. dulaglutide. SURMOUNT-OSA led to FDA approval (December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity, and a 2026 SURMOUNT-OSA post hoc analysis (PMID 42675225) found that improvements in apnea-hypopnea index, body weight, systolic blood pressure and hypoxic burden held regardless of baseline age, sex, AHI severity, BMI or neck circumference — a uniformity result rather than a phenotype map. the phase 2 SYNERGY-NASH trial (PMID 38856224) showed resolution of MASH without worsening of fibrosis in 44-62% of tirzepatide participants versus 10% on placebo, SURMOUNT-MAINTAIN (2026) established that a 5 mg dose preserves most weight loss achieved at MTD, and a Phase 3b psoriasis-plus-obesity trial (PMID 42139049) quintupled the rate of simultaneous PASI 100 skin clearance and ≥10% weight loss vs. ixekizumab alone. Tirzepatide is a genuinely pleiotropic metabolic therapy with an expanding cardiorenal and inflammation-adjacent evidence base, not just a weight-loss drug.

Record-setting weight loss (about 21% of body weight at 15 mg over 72 weeks)
Strong90%
Superior blood sugar control vs semaglutide
Strong90%
Cardiovascular risk reduction
Strong90%
Potential benefits for sleep apnea and NASH
Emerging50%

History & Discovery

Tirzepatide emerged from Eli Lilly's incretin program in the mid-2010s as the first-in-class dual agonist engineered to activate both the GIP and GLP-1 receptors with a single molecule. The design rationale drew on decades of native-incretin biology: GIP and GLP-1 are co-secreted from the gut after meals, and earlier attempts at GIP monotherapy had yielded disappointing metabolic results, but combined activation in rodent and primate studies produced synergistic weight loss and glycemic improvement beyond what either agonist could achieve alone. The molecule's 39-amino-acid backbone combines elements of GIP with a C-20 fatty diacid modification for albumin binding and once-weekly dosing. The SURPASS program (5 Phase III trials, starting with SURPASS-1 in 2021) established FDA approval of Mounjaro for type 2 diabetes in May 2022. The SURMOUNT program then carried the molecule into obesity, with SURMOUNT-1 showing up to 22.5% mean weight loss and leading to Zepbound's FDA approval in November 2023. SURMOUNT-5, the open-label head-to-head against semaglutide at its maximum tolerated dose (1.7 mg or 2.4 mg), confirmed tirzepatide's superiority (20.2% vs 13.7% mean weight loss) and positioned it as the efficacy leader among approved incretin therapies. By mid-2026 the tirzepatide evidence base has broadened well beyond glycemic and body-weight endpoints. The SURPASS-CVOT primary readout (Nicholls et al., NEJM, December 2025, PMID 41406444) established non-inferiority to dulaglutide 1.5 mg for the composite CV outcome across 13,165 T2D patients with ASCVD over a median 4 years, and the FDA added a MACE risk-reduction indication to the Mounjaro label in August 2026, eight months after extending Mounjaro's diabetes indication to children aged 10 and older (December 2025). Companion analyses through 2026 have documented tirzepatide's cardiorenal advantages: a JAMA Cardiology post hoc (Nissen et al., PMID 41903177) mapped the cardiorenal outcome profile in detail, a pre-specified kidney analysis (PMID 42114520) reported a 23% reduction in major kidney events vs. dulaglutide, and a J Am Heart Assoc updated meta-analysis (PMID 42714458) addressed the atrial fibrillation question directly, concluding that tirzepatide was not associated with atrial fibrillation across 10 randomized trials. The obesity-adjacent indication landscape has also matured: SURMOUNT-OSA post hoc analyses (PMID 42675225) report benefit across every baseline subgroup examined rather than identifying a responder phenotype, an Am J Med real-world study (PMID 42735883) characterizes tirzepatide-user cardiorenal outcomes after metabolic and bariatric surgery, and adolescent psychiatric safety of dual GIP/GLP-1 receptor agonists has been evaluated (Diabetes Obes Metab, PMID 42736027) as pediatric expansion planning proceeds. On the compounding front, a JAAD case report (PMID 42598502) documenting inflammation-mediated facial nodules from compounded tirzepatide provides concrete adverse-event evidence supporting the compounded-product-quality caveats already carried in this file, and a JAMA Health Forum analysis of the postshortage compounded GLP-1 RA market (PMID 42467450) empirically documents that compounded activity persists after FDA's December 2024 determination that the shortage was resolved — meaningful clinical context for patients weighing branded vs. compounded sourcing.

How It Works

Tirzepatide activates two appetite-control hormones at once (GIP and GLP-1), producing a stronger 'full' signal than drugs targeting just one. It also improves how your body handles blood sugar and may help your fat cells work more efficiently.

Tirzepatide is a 39-amino acid peptide with dual agonism at GIPR (primary) and GLP-1R. GIP receptor activation in adipose tissue improves lipid handling and insulin sensitivity. Combined GLP-1R/GIPR activation in the hypothalamus produces synergistic appetite suppression. The C-20 fatty diacid enables albumin binding for weekly dosing. GIPR agonism may also enhance beta-cell function and reduce inflammation. The dual mechanism explains the superior efficacy compared to selective GLP-1R agonists.

Evidence Snapshot

Overall Confidence96%

Human Clinical Evidence

Extensive. SURPASS and SURMOUNT trial programs. FDA-approved for T2D and obesity. SURMOUNT-5 head-to-head confirmed superiority over semaglutide (20.2% vs 13.7%). SURMOUNT-MAINTAIN (2026, Lancet) established that a 5 mg maintenance dose preserves most of the weight loss obtained at higher doses, while placebo regains substantially. SURPASS-CVOT primary readout (NEJM 2025, PMID 41406444) established non-inferiority to dulaglutide 1.5 mg for the composite CV outcome across 13,165 patients over a median 4 years (HR 0.92, 95.3% CI 0.83–1.01), leading to a MACE risk-reduction indication on the Mounjaro label in August 2026, with a JAMA Cardiology cardiorenal post hoc (PMID 41903177) and the pre-specified kidney analysis (PMID 42114520) showing a 23% reduction in major kidney events vs dulaglutide. A J Am Heart Assoc updated meta-analysis of 10 RCTs and 6,515 individuals (PMID 42714458) found tirzepatide was not associated with atrial fibrillation (OR 2.20, 95% CrI 0.81–6.75) or atrial arrhythmia; only the broader any-arrhythmia composite was nominally raised (OR 1.84, 95% CrI 1.04–3.90) on low event counts. A systematic review with Trial Sequential Analysis of 21 placebo-controlled RCTs (8,043 participants at increased cardiovascular risk, PMID 41896878) found no difference in serious adverse events (moderate certainty) and no evidence of a difference in all-cause mortality, though that comparison was underpowered (very low certainty); GI adverse events were increased. SURMOUNT-OSA post hoc analyses (PMID 42675225) report AHI reductions across every baseline subgroup examined, with 68-79% of tirzepatide-treated participants improving an AHI severity category versus 64-70% of placebo participants showing no clinically relevant change. First meta-analysis in Type 1 diabetes showed -9.9 kg weight loss as insulin adjunct.

Animal / Preclinical

Comprehensive. Dual incretin biology well-characterized.

Mechanistic Rationale

Very strong. Both GIP and GLP-1 receptor pathways are well-understood.

Research Gaps & Open Questions

What the current literature has not yet settled about Tirzepatide:

  • 01Long-term cardiovascular outcomes beyond SURPASS-CVOT — the SURPASS-CVOT primary readout (NEJM 2025, PMID 41406444) has now published, with cardiorenal post hoc (JAMA Cardiol, PMID 41903177) and kidney-outcomes (Lancet Diab Endo, PMID 42114520) pre-specified analyses characterizing the tirzepatide-vs-dulaglutide profile across a median 4 years; multi-year outcomes beyond 4–5 years and CVOTs in obesity-without-established-CVD populations remain outstanding. A J Am Heart Assoc meta-analysis (PMID 42714458) found no association with atrial fibrillation, though event counts were low and the wide credible interval leaves the question underpowered rather than settled.
  • 02Long-term data beyond 2–3 years — SURMOUNT-1 extension and SURMOUNT-4 provide roughly 88 weeks of continuous exposure data; truly long-term (5-year-plus) outcomes on sustained use are not yet published.
  • 03Pediatric safety and efficacy — Mounjaro is approved for type 2 diabetes from age 10 (December 2025, based on the 99-patient SURPASS-PEDS trial), but there is no pediatric obesity approval, and studies in adolescents with obesity are early-stage compared to the adolescent liraglutide and semaglutide programs. A 2026 Diabetes Obes Metab paper (PMID 42736027) began characterizing adolescent psychiatric safety across the dual GIP/GLP-1 class, but efficacy and long-term safety in pediatric populations remain uncharacterized in dedicated Phase 3 trials.
  • 04Comparative effectiveness vs retatrutide and other next-generation polyagonists — head-to-head data will determine whether tirzepatide's efficacy ceiling is matched or exceeded.
  • 05Body composition outcomes — the extent to which tirzepatide's superior weight loss is accompanied by disproportionate vs proportionate lean mass loss compared to semaglutide is still being characterized.
  • 06Optimal strategies for maintenance vs de-escalation — SURMOUNT-MAINTAIN (2026) provided the first dedicated answer for one dose-reduction strategy (5 mg preserved most of the weight loss obtained at MTD), but whether even-lower fixed doses, intermittent dosing, or biomarker-guided regimens are equally durable remains open.
  • 07Real-world use around metabolic and bariatric surgery — a 2026 Am J Med study (PMID 42735883) characterized early cardiorenal outcomes in patients with prior GLP-1RA or tirzepatide use undergoing metabolic/bariatric surgery, but optimal peri-surgical management (whether to hold tirzepatide preoperatively, when to restart, whether tirzepatide reduces post-surgical weight regain) is not yet standardized.
  • 08Post-shortage compounded product safety — a 2026 JAMA Health Forum analysis (PMID 42467450) documented continued compounded market activity after the December 2024 shortage resolution, and a 2026 JAAD case report (PMID 42598502) documented inflammation-mediated facial nodules from compounded tirzepatide. Systematic pharmacovigilance for compounded-product-specific adverse events remains under-developed.

Forms & Administration

Weekly SC injection. Mounjaro/Zepbound: 2.5mg starting dose, titrated to 5, 7.5, 10, 12.5, or 15mg. Dose escalation every 4 weeks. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

Both Mounjaro and Zepbound share the same pen strengths and titration framework. Starting dose is 2.5 mg weekly for 4 weeks (non-therapeutic initiation), then 5 mg weekly for 4 weeks, with further escalations at 4-week intervals to 7.5 mg, 10 mg, 12.5 mg, and a maintenance ceiling of 15 mg weekly. For type 2 diabetes (Mounjaro), glycemic target achievement often permits stopping titration at 5, 10, or 15 mg. For chronic weight management (Zepbound), the pivotal SURMOUNT trials used 5 mg, 10 mg, and 15 mg maintenance arms; 10 mg and 15 mg produced the largest weight reductions.

Frequency

Once weekly by subcutaneous injection, on the same day each week, with or without regard to meals. Injection timing can be shifted by up to 4 days if necessary to maintain the weekly cadence.

Timing Considerations

Time of day

Once-weekly: same day each week, consistent time of day. Morning or evening both work — the 5-day half-life makes hour-of-day unimportant.

Relative to meals

With or without food. GI side effects tend to be more manageable when the injection isn't immediately followed by a large meal.

Relative to exercise

Unrelated to training.

Cycle Length

Tirzepatide is intended for indefinite chronic use in both approved indications. The SURMOUNT-4 withdrawal trial demonstrated the same general pattern seen with semaglutide: participants who switched from active drug to placebo after 36 weeks of titration regained roughly 14 percentage points of weight over the following 52 weeks, while those who continued tirzepatide lost an additional 5.5%. The clinical inference is that the underlying condition (obesity) is chronic and pharmacological effect does not persist after discontinuation.

Protocol Notes

Tirzepatide is supplied as a pre-filled single-dose pen injector; no reconstitution, vial-drawing, or needle handling is required. Injection sites are abdomen, thigh, or upper arm, with rotation across sites recommended to minimize injection-site reactions. The 4-week-per-step titration is driven by GI tolerability rather than pharmacokinetics — nausea, vomiting, and diarrhea tend to concentrate in the first week after each dose increase and typically attenuate thereafter. Compared to semaglutide, patient-reported GI side effects are broadly similar in incidence though the distribution across specific symptoms differs slightly. A multi-dose autoinjector pen format has been introduced in some markets, alongside the original single-dose pens.

These doses reflect FDA-labeled protocols for specific indications. Individual dosing, titration pacing, and decisions about maintenance dose selection, dose holds, and discontinuation require clinician supervision and individualized medical evaluation.

Timeline of Effects

Onset

Appetite suppression and early satiety are typically reported within the first week of initiation, including at the sub-therapeutic 2.5 mg starting dose. Measurable weight loss is usually evident by week 4–8, and HbA1c trajectories in diabetic patients begin to diverge from placebo within the first month. Full pharmacological effect requires completing titration, which takes a minimum of 20 weeks to reach 15 mg; most trial-reported weight loss accrues during months 4–14 on maintenance dosing.

Peak Effect

In SURMOUNT-1 (72 weeks, n=2,539), mean weight loss at 15 mg was 20.9%, with the curve still sloping downward at trial end. SURMOUNT-4 extended follow-up to 88 weeks and showed continued weight loss during additional maintenance. SURPASS-2 and SURPASS-4 established HbA1c reductions of 2.0–2.6 percentage points at maintenance doses, reached by month 4–6 and sustained. The consensus clinical observation is that weight-loss curves plateau somewhere between month 18 and month 24 for most responders, though individual trajectories vary.

After Discontinuation

SURMOUNT-4 provided the most rigorous discontinuation data: after 36 weeks of open-label titration, participants randomized to placebo regained ~14% of body weight over the subsequent 52 weeks, while the tirzepatide-continuation arm continued to lose. The pharmacokinetic clearance takes approximately 5 weeks given the ~5-day half-life, but the metabolic and appetite-signal effects reverse over a longer window. The pattern mirrors semaglutide: roughly two-thirds of lost weight is regained within a year of stopping if no other intervention replaces the pharmacological effect.

Monitoring & Measurement

Bloodwork & Labs

  • •HbA1c — primary glycemic endpoint, expect a 2.0–2.5 point drop at 15 mg by 40 weeks
  • •Fasting glucose and fasting insulin (HOMA-IR)
  • •Lipid panel (total, LDL, HDL, triglycerides) — triglycerides often improve before LDL
  • •ALT and AST — hepatic fat drops alongside weight; trend toward normalization is expected
  • •Lipase and amylase at baseline — anchor values for any later pancreatitis workup

Functional & Performance Tests

  • •Body weight (same scale, weekly)
  • •Waist circumference
  • •Home blood pressure cuff
  • •Resting heart rate (wearable) — a 2–5 bpm rise is typical
  • •DEXA scan — the lean-mass question matters more here than with most drugs, because the absolute weight drop is larger

When to Test

Baseline, 12 weeks, 24 weeks; weight and waist weekly at home.

Interpretation & Notes

SURMOUNT and SURPASS data set the target: ~20% body weight loss and 2.0–2.5 point HbA1c drop at 15 mg. Tirzepatide's response is typically larger and earlier than semaglutide — by week 12, most responders are already past the 5% weight-loss mark. Same pancreatitis, gallbladder, and muscle-loss cautions as semaglutide apply, but the larger absolute weight loss makes DEXA and resistance training especially worthwhile here; lean-mass loss averages about 25% of total — the same proportion seen on placebo — but 25% of a very large number is still a large number, and you do not get that muscle back easily. If you're on tirzepatide for metabolic reasons and your HbA1c doesn't drop at least 1.0 point by 24 weeks at a therapeutic dose, investigate adherence and source quality before assuming non-response.

Common Questions

Is tirzepatide better than semaglutide?

In head-to-head trials (SURPASS-2), tirzepatide showed greater HbA1c reduction and weight loss than semaglutide 1mg. The SURMOUNT trials showed 20-26% weight loss with the highest dose, exceeding semaglutide's results.

Can I drop to a lower maintenance dose once I've lost the weight?

Yes, with caveats. SURMOUNT-MAINTAIN (2026) directly tested this: after 60 weeks at the maximum tolerated dose (10 or 15 mg), participants who were dose-reduced to 5 mg for another 52 weeks preserved most of their weight loss (-16.6% from baseline) while the placebo arm regained substantially (-9.9%). Continuing the MTD did marginally better (-21.9%). The practical takeaway is that 5 mg appears to be a viable maintenance dose, but stopping entirely is not — the underlying obesity is chronic. Any dose-reduction strategy should be made with a clinician.

Does tirzepatide do anything beyond weight loss and blood sugar?

Yes, the evidence base has broadened considerably. SURMOUNT-OSA led to FDA approval (December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity. A SURPASS-CVOT pre-specified exploratory analysis (n=13,165, median 4 years) showed a 23% reduction in major kidney events versus dulaglutide. A dedicated trial in HFpEF with obesity showed significant improvements in heart-failure symptoms and exercise capacity. The phase 2 SYNERGY-NASH trial showed resolution of MASH without worsening of fibrosis in 44%, 56% and 62% of participants at 5, 10 and 15 mg versus 10% on placebo, in people with biopsy-confirmed MASH and F2-F3 fibrosis. It was a 190-person dose-finding study, not a phase 3 outcomes trial. A phase 3b trial in psoriasis with obesity found tirzepatide plus ixekizumab quintupled the rate of simultaneous skin clearance and meaningful weight loss versus ixekizumab alone.

How much of the weight I'd lose on tirzepatide is muscle?

Roughly a quarter. The SURMOUNT-1 DXA substudy (160 of the 2,539 participants) found that of the body weight lost, approximately 75% was fat mass and 25% was lean mass — and critically, that same split held in the placebo arm, and stayed consistent across sex, age and weight-loss-tertile subgroups. In other words the ratio looks like ordinary weight loss, not a drug-specific muscle penalty. The absolute lean-mass loss is larger in absolute terms than with semaglutide because the total weight loss is larger. Resistance training and adequate protein intake during active weight loss are the standard mitigation strategies, and DEXA scans before and during therapy are worth considering given the magnitude of the body-composition shift.

What did SURPASS-CVOT actually show, and how does tirzepatide compare to dulaglutide for the kidney?

The primary readout (Nicholls et al., NEJM 2025, PMID 41406444) established tirzepatide non-inferior to dulaglutide 1.5 mg for the composite of cardiovascular death, myocardial infarction, or stroke across 13,165 patients with T2D and ASCVD over a median 4 years (12.2% vs 13.1%; HR 0.92, 95.3% CI 0.83–1.01; superiority not shown, P = 0.09). In August 2026 the FDA added a major-cardiovascular-event risk-reduction indication to the Mounjaro label for adults with T2D at high cardiovascular risk. That is the base case that makes tirzepatide's newer-generation status compatible with the established CV benefit reference. The pre-specified kidney analysis (Lancet Diab Endo 2026, PMID 42114520) went further: tirzepatide reduced the composite major kidney outcome by 23% versus dulaglutide (HR 0.77, p=0.0002), with slower eGFR decline. A JAMA Cardiology cardiorenal post hoc (PMID 41903177) has since mapped these outcomes in more detail. The practical takeaway: for a T2D patient with established CV disease where kidney protection matters, the 2026 SURPASS-CVOT evidence base supports tirzepatide over dulaglutide 1.5 mg.

Do I need to stop tirzepatide before surgery or a procedure with anesthesia?

Tell your surgical and anesthesia team you are on it, well before the day. Both the Mounjaro and Zepbound labels carry a Pulmonary Aspiration During General Anesthesia or Deep Sedation warning: aspiration has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures, and the labels instruct patients to inform their healthcare providers of any planned surgery or procedure. The mechanism is the drug's defining one — delayed gastric emptying means the stomach may still hold food after a standard fasting window, which is what raises aspiration risk under sedation. What the labels do not do is specify how long to hold the drug beforehand, and professional-society guidance has shifted more than once; some centers hold the weekly dose before a procedure, others extend the fasting window or use gastric ultrasound to check. Because there is no single label-mandated answer, this is a decision for the team doing the procedure, made in advance rather than discovered on the morning of surgery. Do not stop long-term therapy on your own without telling the clinician who prescribed it.

Does tirzepatide cause vision problems?

Two separate issues get conflated here. The first is on the label: both Mounjaro and Zepbound carry a Diabetic Retinopathy Complications warning advising that patients with a history of diabetic retinopathy be monitored for progression. This reflects a pattern across diabetes therapies in which rapid improvement in blood sugar can transiently worsen pre-existing retinopathy — it is a reason for eye monitoring if you already have retinopathy, not a reason to avoid the drug. The second is NAION, a form of sudden optic-nerve stroke that has been reported with GLP-1 receptor agonists, mostly in the semaglutide literature. A 2026 review put the relative risk estimates between 1.2 and 4.3 and explicitly framed the finding as a safety signal rather than a contraindication; the absolute risk is low and the data are observational. If you have a history of diabetic retinopathy, or develop sudden painless vision loss in one eye, both are reasons to involve an ophthalmologist promptly.

Is compounded tirzepatide safe? What do the case reports actually show?

FDA's final determination that the tirzepatide shortage was resolved came on December 19, 2024, after it re-examined an October 2024 decision, and enforcement discretion ended on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. That closed most of the legal compounding pathway, and in September 2026 FDA told Empower Pharmacy that adding an ingredient such as niacinamide did not stop its tirzepatide products from being essentially copies of the approved drug. A 2026 JAMA Health Forum analysis (PMID 42467450) documented that compounded market activity persists in high-demand states despite the delisting, and a 2026 JAAD case report (PMID 42598502) documented inflammation-mediated facial nodules from compounded tirzepatide — concrete adverse-event evidence beyond generic quality concerns. Compounded product may include impurities and salt forms not present in Mounjaro or Zepbound, and pharmacovigilance for compounded-specific events is under-developed. Branded product from an FDA-authorized channel is the safer default; compounded material is now a documented adverse-event source rather than a hypothetical one.

Who Tirzepatide Is NOT For

Contraindications
  • •Personal or family history of medullary thyroid carcinoma (MTC) — boxed warning based on rodent C-cell tumor findings shared across the incretin class.
  • •Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — genetic predisposition to medullary thyroid cancer makes this an absolute contraindication per labeling.
  • •Prior serious hypersensitivity reaction (anaphylaxis, angioedema) to tirzepatide or any component of the formulation.
  • •Active pancreatitis or history of recurrent pancreatitis — GLP-1/GIP agonists have been associated with pancreatitis signals in post-marketing surveillance, and tirzepatide carries the class warning.
  • •Pregnancy — animal reproductive toxicity data and the absence of human pregnancy safety data make discontinuation necessary. The Zepbound label says simply that when pregnancy is recognized, the drug should be discontinued; neither current label specifies a pre-conception washout period, so claims of a fixed 1-2 month stop-before-conception rule are not label-based. The practical consideration remains that the roughly 5-day half-life and the long re-titration make unplanned discontinuation disruptive, so timing is worth planning with a clinician rather than improvising.
  • •Breastfeeding — transfer into human milk is not adequately characterized; risk-benefit should be individualized with the prescribing clinician.
  • •Severe gastroparesis or significant gastrointestinal motility disorders — tirzepatide's delayed gastric emptying effect can precipitate symptomatic worsening and, in severe cases, obstruction.
  • •Use under age 18 outside the labeled pediatric indication — Mounjaro is approved for type 2 diabetes in children aged 10 and older (maximum 10 mg weekly), but neither Mounjaro nor Zepbound is approved for weight management or sleep apnea in anyone under 18.
  • •Concurrent use with other GLP-1 receptor agonists — redundant mechanism, amplified GI and hypoglycemia risk, and no incremental benefit.
  • •History of diabetic retinopathy — both labels now carry a Diabetic Retinopathy Complications warning advising monitoring for progression in patients with a history of it. This is a monitoring requirement rather than an absolute bar, and it reflects a pattern seen across incretin therapies where rapid glycemic improvement can transiently worsen existing retinopathy.

Drug & Supplement Interactions

The two principal clinical interaction domains are hypoglycemia risk and altered oral drug absorption. When tirzepatide is combined with insulin or insulin secretagogues (sulfonylureas, meglitinides), hypoglycemia risk rises materially, and downward dose adjustment of the insulin or secretagogue at tirzepatide initiation and each escalation is typically required. Because tirzepatide slows gastric emptying, the rate and in some cases the extent of absorption of concurrently administered oral drugs may be altered — particularly relevant for warfarin (consider INR monitoring after dose changes), levothyroxine (TSH should be rechecked), and potentially narrow-therapeutic-index antiepileptics and immunosuppressants. The FDA label recommends that patients using oral hormonal contraceptives switch to a non-oral method or add a barrier method for 4 weeks after tirzepatide initiation and for 4 weeks after each dose escalation, because contraceptive efficacy may be reduced during these windows; this is a stronger recommendation than for semaglutide and reflects specific pharmacokinetic data. Patients on any chronic oral regimen should review timing and monitoring with their prescribing clinician.

Safety Profile

Safety Information

Common Side Effects

NauseaDiarrheaVomitingConstipationDecreased appetite

Cautions

  • • Same thyroid C-cell tumor boxed warning as GLP-1 agonists
  • • Pancreatitis risk
  • • Gallbladder events
  • • Dose-dependent GI side effects, with a Severe Gastrointestinal Adverse Reactions warning added to both labels (Mounjaro 12/2025, Zepbound 02/2026); Mounjaro is not recommended in severe gastroparesis
  • • Diabetic Retinopathy Complications — both labels advise monitoring patients with a history of diabetic retinopathy for progression
  • • Pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists; both labels instruct patients to tell their clinicians about any planned surgery or procedure

What We Don't Know

Cardiovascular outcomes beyond SURPASS-CVOT's median 4 years, and in people with obesity but without diabetes, are still being studied; SURMOUNT-MMO, which enrolled 15,374 people, is the trial designed to answer the second question and has an estimated primary completion of October 2027. Body-composition effects are better characterized than they were — the SURMOUNT-1 DXA substudy puts lean mass at about 25% of weight lost, the same proportion as placebo — but that substudy was only 160 people. Optimal perioperative management is unsettled: the labels warn about aspiration under anesthesia and instruct patients to disclose planned procedures, without specifying how long to hold the drug beforehand. For reference, a suicidal behavior and ideation warning was removed from the Zepbound label in February 2026.

Myths & Misconceptions

Myth

Tirzepatide is just a stronger version of semaglutide.

Reality

Tirzepatide has a distinct mechanism — it activates both GIP and GLP-1 receptors, whereas semaglutide activates only GLP-1. The dual agonism contributes to the superior weight loss shown in SURMOUNT-5 (20.2% vs 13.7%), and the GIP component has effects on adipose tissue and energy handling that a pure GLP-1 agonist cannot produce. 'Stronger' captures the clinical outcome but misrepresents the pharmacology.

Myth

Because tirzepatide produces more weight loss, it must have worse side effects.

Reality

Head-to-head and meta-analytic data show broadly comparable incidence of GI adverse events between tirzepatide and semaglutide, with differences being relatively modest and distributed across specific symptoms. Tirzepatide's superior efficacy does not come at a proportionally higher GI cost, though individual patients may tolerate one molecule better than the other.

Myth

Compounded tirzepatide from online pharmacies is the same drug as Zepbound.

Reality

Compounded tirzepatide is not FDA-approved, is not bioequivalence-tested, and its active pharmaceutical ingredient may include salt forms or impurities not present in branded Mounjaro or Zepbound. Since FDA's December 19, 2024 determination that the shortage was resolved (with enforcement discretion ending in February and March 2025), much ongoing compounding falls outside the narrow legal 503A pathway, and FDA's September 2026 warning letter to Empower Pharmacy rejected added ingredients such as niacinamide as a way around the 'essentially a copy' rule. That adds regulatory exposure on top of product-quality uncertainty.

Myth

Tirzepatide only works if you don't change your diet — it replaces lifestyle change.

Reality

The SURMOUNT and SURPASS trials all combined tirzepatide with lifestyle intervention (reduced-calorie diet and increased physical activity), and outcomes reflect the combined effect. Tirzepatide makes caloric restriction dramatically easier to sustain by reducing hunger and food reward, but the trial-quantified outcomes presuppose some degree of behavioral engagement. It is not a substitute for all dietary context; it is a tool that makes dietary change more achievable.

Myth

Once you reach your goal weight on tirzepatide you can stop and keep the results.

Reality

SURMOUNT-4 directly tested this: participants who stopped after 36 weeks of titration regained ~14% body weight over the next 52 weeks, while continuation produced additional loss. Obesity is a chronic condition; the pharmacological effect does not persist after discontinuation. Any plan involving cessation should be made with a clinician and include monitoring for weight regain. SURMOUNT-MAINTAIN (2026, PMID 42119587) later demonstrated that dose-reduction to 5 mg preserves most of the weight loss achieved at higher doses — a viable alternative to cessation.

Myth

SURPASS-CVOT proved tirzepatide is superior to dulaglutide for the heart, not just non-inferior.

Reality

The primary composite CV endpoint (NEJM 2025, PMID 41406444) showed non-inferiority to dulaglutide 1.5 mg (HR 0.92, 95.3% CI 0.83–1.01; P = 0.09 for superiority) — a positive verdict for tirzepatide but not a superiority claim on the primary CV composite. Where tirzepatide did show superiority was in the pre-specified kidney analysis (23% reduction in major kidney events, PMID 42114520) and in the cardiorenal outcome profile characterized by the JAMA Cardiology post hoc (PMID 41903177). The distinction matters clinically: tirzepatide's SURPASS-CVOT positioning is 'CV non-inferior with kidney superiority,' not 'CV superior overall.'

Published Research

59 studies

Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review

Systematic ReviewPMID: 42941232

Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy

ReviewPMID: 42857401

Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With Obesity.

Clinical StudyPMID: 42736027

Prior GLP-1RA or Tirzepatide Use and Early Cardiorenal Outcomes After Metabolic and Bariatric Surgery.

Observational StudyPMID: 42735883

Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.

Meta-AnalysisPMID: 42714458

Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.

Randomized Controlled TrialPMID: 42675225

Inflammation-mediated facial nodules to compounded tirzepatide.

Clinical StudyPMID: 42598502

Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.

Observational StudyPMID: 42467450

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial

274 adults with moderate-to-severe psoriasis and overweight/obesity. Adding tirzepatide to ixekizumab quintupled simultaneous PASI 100 + ≥10% weight loss at week 36 (27.1% vs 5.8%), supporting concurrent treatment of psoriasis and obesity as linked metabolic-inflammatory diseases.

Randomized Controlled TrialPMID: 42139049

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN)

The first dedicated maintenance trial. After 60 weeks of open-label tirzepatide at the maximum tolerated dose (10 or 15 mg), participants were randomized to continue MTD, drop to 5 mg, or switch to placebo for 52 more weeks. Mean weight change from baseline to week 112 was -21.9% (continued MTD), -16.6% (dose-reduced to 5 mg), and -9.9% (placebo). Most of the weight-loss benefit was preserved at 5 mg, while placebo regained substantially — establishing that low-dose maintenance is a viable strategy.

Randomized Controlled TrialPMID: 42119587

A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial (Zoungas et al., Lancet Diabetes Endocrinol 2026)

In 13,165 SURPASS-CVOT participants over a median 4.0 years, tirzepatide reduced the composite kidney outcome (macroalbuminuria, persistent ≥50% eGFR drop, kidney failure, or kidney death) by 23% vs dulaglutide (HR 0.77, p=0.0002), with consistent benefit in both low-to-moderate and high-risk CKD subgroups.

Randomized Controlled TrialPMID: 42114520

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

JAMA Cardiology SURPASS-CVOT post hoc cardiorenal analysis, companion to the pre-specified kidney-outcomes paper (PMID 42114520). The composite cardiorenal endpoint occurred in 23.7% of tirzepatide-treated patients versus 27.4% on dulaglutide (HR 0.84, 95% CI 0.79-0.90, P<0.001) in type 2 diabetes with established cardiovascular disease over a median 4 years.

Randomized Controlled TrialPMID: 41903177

The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis (Sillassen et al., BMC Med 2026)

21 placebo-controlled trials (8,043 participants at increased cardiovascular risk). No difference in serious adverse events (OR 0.98; adequately powered, moderate certainty) and no evidence of a difference in all-cause mortality (OR 1.02; underpowered, very low certainty). Tirzepatide increased non-serious adverse events, mainly nausea, diarrhea, decreased appetite, and vomiting.

Meta-AnalysisPMID: 41896878

Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis (Soliman et al., J Diabetes Metab Disord 2026)

First meta-analysis of tirzepatide in Type 1 diabetes (6 studies, 248 adults) as an insulin adjunct: HbA1c decreased 0.61% and weight fell 9.9 kg. Treat with caution on two counts — the six included studies are observational rather than randomized, and the paper's reported BMI reduction of 8.3 kg/m² is arithmetically incompatible with a 9.9 kg weight loss at any adult height, so at least one of its summary figures is wrong.

Meta-AnalysisPMID: 41883513

Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials (Ciudin et al., Adv Ther 2026)

Meta-AnalysisPMID: 41820778

A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial (le Roux et al., Diabetes Obes Metab 2026)

Post hoc analysis of the head-to-head trial: 23-34% of tirzepatide patients reached proposed treat-to-target thresholds (waist-to-height ratio below 0.53, BMI below 27, or both) vs 14-21% on semaglutide. About 77% of those who reached the waist-to-height target achieved low disease activity to remission.

Randomized Controlled TrialPMID: 41635114

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (Nicholls et al., NEJM 2025 — SURPASS-CVOT)

SURPASS-CVOT primary publication. 13,165 adults with type 2 diabetes and atherosclerotic cardiovascular disease (modified intention-to-treat) were randomized to weekly tirzepatide (up to 15 mg) or dulaglutide 1.5 mg. Cardiovascular death, myocardial infarction, or stroke occurred in 12.2% vs 13.1% (HR 0.92, 95.3% CI 0.83–1.01): non-inferior (P = 0.003) but not superior (P = 0.09). Adverse events were similar overall, with more GI events on tirzepatide.

Randomized Controlled TrialPMID: 41406444

A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults

Meta-AnalysisPMID: 41039116

Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial

Randomized Controlled TrialPMID: 40975112

Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients

Meta-AnalysisPMID: 40892610

Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis

Meta-AnalysisPMID: 40813122

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)

The head-to-head the page's superiority claim rests on, asserted in five sections and previously uncited. An open-label phase 3 trial comparing tirzepatide with semaglutide at its maximum tolerated dose (1.7 mg or 2.4 mg) in adults with obesity, showing 20.2% versus 13.7% mean weight reduction. The open-label design is a real limitation for subjective and behavioral outcomes, though less so for weight itself.

Randomized Controlled TrialPMID: 40353578

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis

Meta-AnalysisPMID: 40186344

Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies

Meta-AnalysisPMID: 40184508

Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight

Randomized Controlled TrialPMID: 39996356

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis

Meta-AnalysisPMID: 39903735

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis

Meta-AnalysisPMID: 39719170

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

The SUMMIT trial. 731 patients with heart failure, ejection fraction at least 50% and BMI at least 30, followed a median 104 weeks. Cardiovascular death or a worsening heart-failure event occurred in 9.9% on tirzepatide versus 15.3% on placebo (HR 0.62, 95% CI 0.41-0.95), and the KCCQ clinical summary score improved 6.9 points more than placebo. This is a trial result, not a regulatory one — tirzepatide has no FDA heart-failure indication.

Randomized Controlled TrialPMID: 39555826

Tirzepatide for Obesity Treatment and Diabetes Prevention

Three-year SURMOUNT-1 extension data showed sustained 19.7% weight loss at the 15mg dose with dramatically lower progression to type 2 diabetes.

Randomized Controlled TrialPMID: 39536238

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials

Meta-AnalysisPMID: 39305981

Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials

Meta-AnalysisPMID: 39037553

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)

The two phase 3 trials behind the December 2024 FDA sleep-apnea approval, in adults with moderate-to-severe obstructive sleep apnea and obesity. Previously the page cited only the 2026 post hoc subgroup analysis, not the primary publication the approval was based on.

Randomized Controlled TrialPMID: 38912654

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH)

A phase 2 dose-finding trial in 190 participants with biopsy-confirmed MASH and F2-F3 fibrosis. The primary endpoint was resolution of MASH without worsening of fibrosis at 52 weeks, reached by 44%, 56% and 62% at 5, 10 and 15 mg versus 10% on placebo. It is not a liver-fat trial, and it is not phase 3.

Randomized Controlled TrialPMID: 38856224

Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial

Meta-AnalysisPMID: 38850440

Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians

Meta-AnalysisPMID: 38639549

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

Meta-AnalysisPMID: 38613667

Evidence that tirzepatide protects against diabetes-related cardiac damages

Meta-AnalysisPMID: 38555463

Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis

Meta-AnalysisPMID: 38413012

Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials

Meta-AnalysisPMID: 38356942

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

Meta-AnalysisPMID: 38286487

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

Randomized Controlled TrialPMID: 38078870

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis

Meta-AnalysisPMID: 38029929

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

Meta-AnalysisPMID: 37908750

Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus

Meta-AnalysisPMID: 37828829

Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials

Meta-AnalysisPMID: 37700437

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials

Meta-AnalysisPMID: 37460681

Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis

Meta-AnalysisPMID: 37253796

Weight loss efficiency and safety of tirzepatide: A Systematic review

Systematic ReviewPMID: 37141329

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Meta-AnalysisPMID: 37024129

Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials

Meta-AnalysisPMID: 36579723

Tirzepatide Once Weekly for the Treatment of Obesity

The pivotal SURMOUNT-1 trial (n=2,539) showed tirzepatide produced up to 20.9% weight loss at the 15mg dose — the largest reduction ever seen in an obesity drug trial at the time.

Clinical TrialPMID: 35658024

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Meta-AnalysisPMID: 35579691

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

Meta-AnalysisPMID: 35210595

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)

The glycemic head-to-head against semaglutide 1 mg: HbA1c fell 2.01, 2.24 and 2.30 percentage points at 5, 10 and 15 mg of tirzepatide versus 1.86 points on semaglutide. The margin is real but narrower than the page's earlier framing implied.

Randomized Controlled TrialPMID: 34170647

ZEPBOUND (tirzepatide) injection prescribing information (DailyMed)

Regulatory

MOUNJARO (tirzepatide) injection prescribing information (DailyMed)

Regulatory

FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolution, December 19, 2024, and enforcement timelines)

Regulatory

FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list (April 30, 2026)

Regulatory

FDA warning letter to Empower Clinic Services, LLC dba Empower Pharmacy (September 18, 2026)

Regulatory

Popular Stacks Including Tirzepatide

Tirzepatide Compared

GLP-1 Agonists: Semaglutide vs Tirzepatide vs Retatrutide
GLP-1 receptor agonists have transformed the weight management and metabolic health landscape. Semaglutide (Ozempic®/Wegovy®) was the breakthrough, Tirzepatide (Mounjaro®/Zepbound®) raised the bar with dual-agonism, and Retatrutide represents the next frontier as a triple agonist. All three reduce appetite and improve metabolic markers, but they differ meaningfully in mechanism, efficacy magnitude, side effect profiles, and regulatory status. This comparison helps you understand the evolving landscape.
Semaglutide vs Tirzepatide
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the two most prescribed GLP-1 medications for weight loss and type 2 diabetes. The head-to-head SURMOUNT-5 trial settled the efficacy question — tirzepatide produces greater weight loss — but the choice between them involves insurance coverage, availability, tolerability, and individual response.
Retatrutide vs Tirzepatide
Retatrutide and tirzepatide are Eli Lilly's two flagship next-generation obesity peptides — closely related 39-amino-acid molecules with one defining difference. Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management, and obstructive sleep apnea in adults with obesity). Retatrutide adds a third receptor — glucagon — and is the first triple agonist to complete pivotal Phase 3 obesity trials: TRIUMPH-1 (NEJM, September 2026) reported 25.0% mean weight loss at 12 mg over 80 weeks, and TRIUMPH-2 (Lancet, September 2026) reported 18.8% in adults with type 2 diabetes. Retatrutide is not FDA-approved; Lilly plans to submit it to the FDA in Q1 2027. This comparison is the honest 'dual vs triple' breakdown, with the trade-offs that the cross-trial weight-loss numbers conceal.

Quick Facts

Class
Dual GIP/GLP-1 Receptor Agonist
Tier
S
Evidence
Strong
Safety
Well-Studied
Updated
Nov 2026
Citations
59PubMed

Also known as

MounjaroZepboundLY3298176

Tags

Weight LossMetabolic HealthFDA-ApprovedGLP-1GIP

Evidence Score

Overall Confidence96%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.